Navigation Links
Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
Date:3/15/2012

A team of researchers from the Ottawa Hospital Research Institute (OHRI) and the University of Ottawa (uOttawa) has been awarded $367,000 from the Canadian Institutes of Health Research (CIHR) and $75,000 from the Stem Cell Network to lead the first clinical trial in the world of a stem cell therapy for septic shock. This deadly condition occurs when an infection spreads throughout the body and over-activates the immune system, resulting in severe organ damage and death in 30 to 40 per cent of cases. Septic shock accounts for 20 per cent of all Intensive Care Unit (ICU) admissions in Canada and costs $4 billion annually. Under the leadership of Dr. Lauralyn McIntyre, this new "Phase I" trial will test the experimental therapy in up to 15 patients with septic shock at The Ottawa Hospital's ICU.

The treatment involves mesenchymal stem cells, also called mesenchymal stromal cells or MSCs. Like other stem cells, they can give rise to a variety of more specialized cells and tissues and can help repair and regenerate damaged organs. They also have a unique ability to modify the body's immune response and enhance the clearance of infectious organisms. They can be found in adult bone marrow and other tissues, as well as umbilical cord blood, and they seem to be easily transplantable between people, because they are more able to avoid immune rejection.

There has been a great deal of interest in using MSCs to treat disease, with most research so far focused on heart disease, stroke, inflammatory bowel disease and blood cancers. Hundreds of patients with these diseases have already been treated with MSCs through clinical trials, with results suggesting that these cells are safe in these patients, and have promising signs of effectiveness. MSCs are still considered experimental however, and have not been approved by Health Canada as a standard therapy for any disease.

In recent years, a number of animal studies have suggested that MSCs may a
'/>"/>

Contact: Jennifer Ganton
jganton@ohri.ca
613-798-5555 x73325
Ottawa Hospital Research Institute
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. UNH researchers find African farmers need better climate change data to improve farming practices
2. Researchers attempt to solve problems of antibiotic resistance and bee deaths in one
3. UC Santa Barbara researchers discover genetic link between visual pathways of hydras and humans
4. Study by UC Santa Barbara researchers suggests that bacteria communicate by touch
5. University of Tennessee researchers invent device to rapidly detect infectious disease
6. Researchers find safer way to use common but potentially dangerous medication
7. SFU researchers help discover new HIV vaccine-related tool
8. Notre Dame researchers are providing insights into elephant behavior and conservation issues
9. Researchers develop worlds first biodegradable joint implant
10. Researchers identify novel pathway responsible for infection of a common STD pathogen
11. Researchers discover how vitamin D inhibits inflammation
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
(Date:7/28/2014)... additional coral communities showing signs of damage from the Deepwater ... spill in the Gulf of Mexico. The discovery was made ... at Penn State University. A paper describing this work and ... of Mexico will be published during the last week of ... Proceedings of the National Academy of Sciences . , ...
(Date:7/28/2014)... -- Fifteen years ago, MIT professor John Essigmann and colleagues ... an HIV drug. They thought if they could induce the ... and eventually die out a strategy that our immune ... such a drug, which caused HIV to mutate at an ... virus from patients in a small clinical trial reported in ...
(Date:7/28/2014)... other forms of dementia, but the research community is ... Washington bioengineers have a designed a peptide structure that ... proteins into a state that,s linked to widespread diseases ... and Lou Gehrig,s disease. The synthetic molecule blocks these ... an abnormally folded form by targeting a toxic intermediate ...
Breaking Biology News(10 mins):Impact of Deepwater Horizon oil spill on coral is deeper and broader than predicted 2Forced mutations doom HIV 2Forced mutations doom HIV 3Forced mutations doom HIV 4New protein structure could help treat Alzheimer's, related diseases 2New protein structure could help treat Alzheimer's, related diseases 3
... Institute Associate Professor Marisa Roberto has been awarded the ... the Ordine al Merito della Repubblica Italiana (Order of ... addictive behavior. Traditionally bestowed by the president ... "merit acquired by the nation" in literature, the arts, ...
... been told you,re going on a trip. The only problem ... traveling, or what you,ll do when you get there. ... is on right now. As land use, human population, consumption ... with complex and unpredictable interactions, it,s anybody,s guess where we,ll ...
... recent book chapter about sugar-based chemicals is topping ... list. "Sugar-Based Chemicals for Environmentally Sustainable Applications" ... http://pubs.acs.org/doi/abs/10.1021/bk-2010-1061.ch001 and is racking up kudos. ... and research professors A. J. East and W. ...
Cached Biology News:U of M researchers find smart decisions for changing environmental times 2Sugar-based chemicals book chapter by NJIT professor takes ACS kudos 2
(Date:7/29/2014)... DALLAS , July 29, 2014 ... Market Slide Scanners (Whole Slide Imaging), Analytics (Image Analysis Software), ... Storage - Global Forecasts & Trends to 2018", published ... and restraints in geographies such as North ... Asia , and the Rest of the ...
(Date:7/29/2014)... 29, 2014 /PRNewswire-iReach/ -- Nanosyn, Inc. announced today ... Inc., to provide access to Nanosyn,s microfluidics screening ... platform for novel small molecule therapeutics. ... to work with FORMA Therapeutics to explore key ... homeostasis. FORMA Therapeutics, decision to work with us ...
(Date:7/29/2014)... 2014  Cannabis Science, Inc. (OTC: CBIS), a ... and related consulting, applauds the Editorial Board of ... position in opposition to current federal law on ... The New York Times also announces a series ... the issue called "High Time:  An Editorial Series ...
(Date:7/29/2014)... Denver, CO (PRWEB) July 29, 2014 ... and soiled linen collection and transport solutions for hospitals, ... Society for Healthcare Engineering (ASHE) Annual Conference & Technical ... TransVac will present its technology for making hospitals cleaner, ... operational costs over the hospital’s life cycle. Staff ...
Breaking Biology Technology:Digital Pathology Market worth $437 Million by 2018 2Digital Pathology Market worth $437 Million by 2018 3Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 3TransVac Presents Cost Saving Technology at ASHE Conference for Keeping Hospitals Cleaner 2
... , PHILADELPHIA, July 13 ERT (Nasdaq: ... technology, and other services to the biopharmaceutical, medical device, and related ... 2009 second quarter on Thursday, July 30, 2009 after the market ... at 5:00 PM EDT that day. , , ...
... , SAN JOSE, Calif., July ... of measurement and control solutions for biologics applications today announced ... BIIB ) aimed at evaluating emerging technologies for single-use bioprocessing. ... control algorithms. , , ...
... LEXINGTON, Mass. and HEIDELBERG, Germany, July 13 ... first human cancer biochip for HybSelect, febit,s highly automated technology for ... biochip features 115 important genes which are reported to be associated ... , , "Molecular signatures defined ...
Cached Biology Technology:ERT to Announce 2009 Second Quarter Results on July 30, 2009 2Finesse Solutions Forges Agreement With Leading Biotechnology Company for Single-Use Technology Exploration 2First Catalog Cancer Biochip for Sequence Capture Now Available from febit 2
Activating Agents, 7-azabenzotriazol-1-yloxy-tris-(pyrrolidino)phosphonium hexafluorophosphate...
Each 72-well MiniTray is low profile, with lid. Conical well shape, 10 l....
The E. coli Expression System with Gateway Technology is designed to create E. coli expression clones containing the T7 promoter. The expression clones are ready for transformation and expression in ...
...
Biology Products: